

SEQUENT SCIENTIFIC LIMITED
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 SEPTEMBER 2012

(₹ in Lakhs)

| S.No. | Particulars | STANDALONE | | | | | |
|----------------|---|------------------------|------------------------|------------------------|------------------------|------------------------|----------------------|
| | | Quarter Ended | | | Half Year Ended | | Year Ended |
| | | 30-Sep-12 UNAUDITED | 30-Jun-12 UNAUDITED | 30-Sep-11 UNAUDITED | 30-Sep-12 UNAUDITED | 30-Sep-11 UNAUDITED | 31-Mar-12 AUDITED |
| Part-1 | | | | | | | |
| 1 | Income from operations | | | | | | |
| a | Net Sales / Income from Operations (net of excise duty) | 6,295.80 | 7,166.20 | 8,919.40 | 13,462.00 | 15,780.90 | 33,188.00 |
| b | Other Operating Income | 3.60 | 14.90 | - | 18.50 | - | 55.20 |
| | Total income from operations (net) | 6,299.40 | 7,181.10 | 8,919.40 | 13,480.50 | 15,780.90 | 33,243.20 |
| 2 | Expenses | | | | | | |
| a | Cost of materials consumed | 3,673.50 | 3,289.10 | 5,700.61 | 6,962.60 | 9,250.11 | 18,074.80 |
| b | Purchase of stock-in-trade | 190.90 | 157.90 | 265.89 | 348.80 | 423.59 | 851.30 |
| c | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (573.70) | 441.80 | (621.20) | (131.90) | (410.30) | 61.20 |
| d | Employee benefits expenses | 787.60 | 607.80 | 686.80 | 1,395.40 | 1,319.10 | 2,543.70 |
| e | Depreciation and amortisation expenses | 738.00 | 561.60 | 458.98 | 1,299.60 | 901.73 | 2,102.80 |
| f | Other expenses | 2,447.90 | 3,096.90 | 2,874.08 | 5,544.80 | 4,457.25 | 8,165.00 |
| | Total expenses | 7,264.20 | 8,155.10 | 9,365.16 | 15,419.30 | 15,941.48 | 31,798.80 |
| 3 | Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2) | (964.80) | (974.00) | (445.76) | (1,938.80) | (160.58) | 1,444.40 |
| 4 | Other Income | 1,028.70 | 86.40 | 99.40 | 1,115.10 | 674.60 | 1,132.70 |
| 5 | Profit/(Loss) from ordinary activities before finance cost and exceptional items (3±4) | 63.90 | (887.60) | (346.36) | (823.70) | 514.02 | 2,577.10 |
| 6 | Finance cost | 691.00 | 736.30 | 672.82 | 1,427.30 | 1,338.25 | 2,826.50 |
| 7 | Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5±6) | (627.10) | (1,623.90) | (1,019.18) | (2,251.00) | (824.23) | (249.40) |
| 8 | Exceptional items | - | - | - | - | - | - |
| 9 | Profit/(Loss) from ordinary activities before tax (7±8) | (627.10) | (1,623.90) | (1,019.18) | (2,251.00) | (824.23) | (249.40) |
| 10 | Tax Expense | (209.00) | (105.90) | 31.17 | (314.90) | 176.24 | (396.40) |
| 11 | Net Profit/(Loss) from Ordinary activities after tax (9±10) | (418.10) | (1,518.00) | (1,050.35) | (1,936.10) | (1,000.47) | 147.00 |
| 12 | Extraordinary items | - | - | - | - | - | - |
| 13 | Net Profit/(Loss) for the period(11±12) | (418.10) | (1,518.00) | (1,050.35) | (1,936.10) | (1,000.47) | 147.00 |
| 14 | Paid-up equity share capital (Face Value per share Rs.10 each) | 2,193.50 | 2,193.50 | 2,193.50 | 2,193.50 | 2,193.50 | 2,193.50 |
| 15 | Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year | - | - | - | - | - | 10,537.20 |
| 16.i | Earnings Per Share before Extraordinary Items for the period (Non-Annualised) | | | | | | |
| | Basic (Rs.) | (1.91) | (6.92) | (4.79) | (8.83) | (4.56) | 0.67 |
| | Diluted (Rs.) | (1.91) | (6.92) | (4.79) | (8.83) | (4.56) | 0.67 |
| 16.ii | Earnings Per Share after Extraordinary Items for the period (Non-Annualised) | | | | | | |
| | Basic (Rs.) | (1.91) | (6.92) | (4.79) | (8.83) | (4.56) | 0.67 |
| | Diluted (Rs.) | (1.91) | (6.92) | (4.79) | (8.83) | (4.56) | 0.67 |
| Part-II | | | | | | | |
| A | PARTICULARS OF SHAREHOLDING | | | | | | |
| 1 | Public Shareholding | | | | | | |
| | No. of Shares | 9,500,680 | 9,692,781 | 6,028,969 | 9,500,680 | 6,028,969 | 9,745,212 |
| | % of Share Holding | 43.31% | 44.19% | 27.49% | 43.31% | 27.49% | 44.43% |
| 2 | Promoters and Promoter Group Shareholding | | | | | | |
| a) | Pledged / Encumbered | | | | | | |
| 1. | No. of shares | 1,000,000 | 1,000,000 | 10,300,000 | 1,000,000 | 10,300,000 | 1,000,000 |
| 2. | Percentage of shares (as a % of the total shareholding of promoter & promoter group) | 8.04% | 8.17% | 64.75% | 8.04% | 64.75% | 8.20% |
| 3. | Percentage of shares (as a % of the total share capital of the company) | 4.56% | 4.56% | 46.96% | 4.56% | 46.96% | 4.56% |
| b) | Non-encumbered | | | | | | |
| 1. | No. of shares | 11,434,511 | 11,242,410 | 5,606,222 | 11,434,511 | 5,606,222 | 11,189,979 |
| 2. | Percentage of shares(as a % of the total shareholding of promoter & promoter group) | 91.96% | 91.83% | 35.25% | 91.96% | 35.25% | 91.80% |
| 3. | Percentage of shares (as a % of the total share capital of the company) | 52.13% | 51.25% | 25.55% | 52.13% | 25.55% | 51.01% |
| B | INVESTOR COMPLAINTS | | | | | | |
| | Pending at the beginning of the quarter | | | | | | NIL |
| | Received during the quarter | | | | | | 5 |
| | Disposed of during the quarter | | | | | | 5 |
| | Remaining unresolved at the end of the quarter | | | | | | NIL |

STATEMENT OF ASSETS AND LIABILITIES

| S.No. | Particulars | STANDALONE | |
|------------|---|------------------------|------------------------|
| | | As at 30th Sep 2012 | As at 31st Mar 2012 |
| I. | EQUITY AND LIABILITIES | | |
| 1 | Shareholders' funds | | |
| | (a) Share capital | 2,134.00 | 2,134.00 |
| | (b) Reserves and surplus | 8,600.70 | 10,537.30 |
| | (c) Money received against share warrants | 633.90 | - |
| | Sub-total-Shareholder's fund | 11,368.60 | 12,671.30 |
| 2 | Non-current liabilities | | |
| | (a) Long-term borrowings | 9,707.70 | 6,226.50 |
| | (b) Deferred tax liabilities (Net) | 509.20 | 824.10 |
| | (c) Long-term provisions | 358.00 | 401.90 |
| | Sub-total-Non-current liabilities | 10,574.90 | 7,452.50 |
| 3 | Current liabilities | | |
| | (a) Short-term borrowings | 11,499.40 | 9,808.70 |
| | (b) Trade payables | 11,931.40 | 12,257.40 |
| | (c) Other current liabilities | 2,140.40 | 7,160.10 |
| | (d) Short-term provisions | 358.00 | 291.70 |
| | Sub-total-Current liabilities | 25,929.20 | 29,517.90 |
| | TOTAL - EQUITY AND LIABILITIES | 47,872.70 | 49,641.70 |
| II. | ASSETS | | |
| 1 | Non-current assets | | |
| | (a) Fixed assets | 22,399.90 | 22,385.60 |
| | (b) Non-current investments | 3,881.40 | 3,881.40 |
| | (c) Long-term loans and advances | 1,793.30 | 1,629.80 |
| | (d) Other non-current assets | 44.90 | 332.40 |
| | Sub-total-Non-current assets | 28,119.50 | 28,229.20 |
| 2 | Current assets | | |
| | (a) Current investments | 17.70 | 27.70 |
| | (b) Inventories | 6,175.80 | 6,310.80 |
| | (c) Trade receivables | 7,191.70 | 8,248.00 |
| | (d) Cash and cash equivalents | 760.70 | 1,576.70 |
| | (e) Short-term loans and advances | 5,130.90 | 4,211.50 |
| | (f) Other current assets | 476.40 | 1,037.80 |
| | Sub-total-Current assets | 19,753.20 | 21,412.50 |
| | TOTAL - ASSETS | 47,872.70 | 49,641.70 |

Notes:

- The unaudited financial results were taken on record by the Board of Directors at its meeting held on November 07, 2012.
- The Statutory Auditors have performed a limited review of the standalone financial results for the period ended as on September 30, 2012 of the Company as required by Clause 41 of the Listing Agreement.
- Segment Results
The company has identified Pharmaceuticals and Specialty Chemicals as its business segments, Segments have been identified taking in to account the nature of products, the differing risks & returns, the organisational structure & the internal reporting system.

| Sl. No | Particulars | Quarter Ended | | | Half Year Ended | | Year Ended |
|----------|---|------------------------|------------------------|------------------------|------------------------|------------------------|----------------------|
| | | 30-Sep-12 UNAUDITED | 30-Jun-12 UNAUDITED | 30-Sep-11 UNAUDITED | 30-Sep-12 UNAUDITED | 30-Sep-11 UNAUDITED | 31-Mar-12 AUDITED |
| 1 | Segment Revenue | | | | | | |
| | a) Pharmaceuticals | 5,066.58 | 6,247.83 | 7,715.38 | 11,314.41 | 13,582.93 | 28,213.31 |
| | b) Specialty Chemicals | 1,232.82 | 933.27 | 1,204.02 | 2,166.09 | 2,197.97 | 5,029.89 |
| | Net Sales /Income from Operations | 6,299.40 | 7,181.10 | 8,919.40 | 13,480.50 | 15,780.90 | 33,243.20 |
| 2 | Segment Results | | | | | | |
| | Profit or Loss before Tax and Interest from Each Segment | | | | | | |
| | a) Pharmaceuticals | (1.94) | (684.49) | 123.69 | (686.43) | 312.75 | 1,109.73 |
| | b) Specialty Chemicals | 237.42 | (108.44) | 157.60 | 128.98 | 408.40 | 1,085.62 |
| | Total | 235.48 | (792.93) | 281.29 | (557.45) | 721.15 | 2,195.35 |
| | Less (i) Finance Cost | 691.00 | 736.30 | 672.82 | 1,427.30 | 1,338.25 | 2,826.50 |
| | (ii) other unallocable expenditure net off unallocable income | 171.58 | 94.67 | 627.65 | 266.25 | 207.13 | (381.75) |
| | Total Profit Before Tax | (627.10) | (1,623.90) | (1,019.18) | (2,251.00) | (824.23) | (249.40) |
| 3 | Capital Employed | | | | | | |
| | a) Pharmaceuticals | 24,833.43 | 24,579.05 | 21,900.16 | 24,833.43 | 21,900.16 | 17,816.86 |
| | b) Specialty Chemicals | 890.28 | 1,107.35 | 2,578.88 | 890.28 | 2,578.88 | 2,844.96 |
| | c) Unallocated | (14,355.11) | (14,533.10) | (12,895.53) | (14,355.11) | (12,895.53) | (7,990.52) |
| | Total | 11,368.60 | 11,153.30 | 11,583.51 | 11,368.60 | 11,583.51 | 12,671.30 |

4. Figures for previous periods have been regrouped and rearranged, wherever necessary, to conform to the relevant current period classification.

For Sequent Scientific Limited

Place: Bangalore
Date : November 07, 2012

Dr. Gautam Kumar Das
Executive Director